Aurobindo Pharma Ltd said its wholly owned arm, Auro Pharma Ltd, has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Ltd on a going-concern basis. The all-cash transaction is valued at ₹325 cr.
The company’s exchange filing stated that the acquisition was completed through a Business Transfer Agreement (BTA) and is effective from January 1, 2026.
The acquired business includes 23 brands marketed across 67 SKUs and nine pipeline products, with major portfolios in anti-infective and pain management. The business employs around 470 field staff and has a distribution network comprising over 1,600 stockists and related infrastructure. In FY2024-25, the business recorded a turnover of ₹1,135.3 million with an EBITDA of ₹289.9 million, according to the exchange filing.
Founded in 1973-74, Khandelwal Laboratories operates in India and specialises in branded oncology and non-oncology prescription formulations. The acquisition will help Auro Pharma strengthen its presence in the domestic pharmaceutical market and complement its existing product portfolio in pain management and anti-infective segments.
Auro Pharma’s managing team said the acquisition will enhance the company’s growth prospects and provide a wider range of prescription offerings to the domestic market.
Shares of Aurobindo Pharma Ltd ended higher on Thursday, January 1, by 1.18% at ₹1,197.00 on the NSE.
Also Read: Aurobindo Pharma shares little changed after unit CuraTeQ terminates agreement with BioFactura
